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Abstract
Background: Matrix metalloproteinases (MMPs),
especially MMP-2 and MMP-9, play an important role
in tumor invasion and metastasis. This study aimed
to determine the serum levels of MMP-2, MMP-9, 130-
and 225-kDa gelatinolytic bands and conventional
tumor markers, carcinoembryonic antigen (CEA) and
cancer antigen (CA) 19-9, in patients with gastrointes-
tinal cancers. The relationship between these para-
meters and clinicopathological factors was also
studied.
Methods: Sera from controls (ns19), and patients
with colorectal (ns47) and gastric (ns34) cancer
were collected prospectively. The gelatinolytic activi-
ties of MMP-2, MMP-9, 130- and 225-kDa bands were
determined using gelatin zymography. CEA and CA
19-9 were determined using immunoradiometric
assay (IRMA).
Results: Serum levels of MMP-9, 130- and 225-kDa
gelatinolytic bands, CEA, and CA 19-9, but not MMP-
2, in colorectal and gastric cancer were significantly
higher than that of controls. No significant correlation
was found between histological grade or clinical
stage and levels of MMP-9, 130- and 225-kDa gelati-
nolytic bands, which were correlated (rs0.61–0.89,
p-0.005).
Conclusions: Our findings suggest that zymographic
determination of MMP-9, 130- and 225-kDa gelatino-
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lytic bands in colorectal and gastric cancer may be
useful in studying these types of cancer in parallel
with conventional tumor markers.
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Introduction
Remodeling of normal and diseased tissue, whose
etiology includes matrix degradation or fibrosis, are
thought to result from alterations in the balance
between matrix metalloproteinases (MMPs) and
tissue inhibitor metalloproteinases (TIMPs) (1). The
first barrier for an invading epithelial tumor is the
basement membrane, consisting primarily of type IV
collagen. The type IV collagenases, matrix metallo-
proteinase-2 (MMP-2) and MMP-9 (constitutive and
inducible gelatinase, respectively), degrade type IV
and V collagen, gelatin, and fibronectin (2).
The role of MMP-2 and MMP-9 has been confirmed
in colorectal cancer (3–5) and gastric cancer (6–8).
Increased levels of MMP-2 and MMP-9 in patients
with colorectal and gastric cancer were detected in
serum (9, 10), plasma (3, 9), and tissue (3, 11, 12).
Different techniques were utilized for the determina-
tion of MMP-2 and MMP-9 including gelatin zymogra-
phy (11, 13), enzyme linked immunosorbant assay
(ELISA) (3, 14), immunohistochemical techniques (15),
in situ hybridization (2) and reverse transcriptase-
polymerase chain reaction (3).
In addition to MMP-2 and MMP-9, the 130- and 225-
kDa gelatinolytic bands were detected in zymographic
analysis of serum samples and found to be increased
in different types of cancer (12, 16). It was confirmed
that these bands are MMPs (17). The 225-kDa band
corresponded to pro-MMP-9 dimers, while the 130-
kDa band had the same molecular size as the MMP-
9-lipocalin-2 complex found primarily in neutrophils
and other cell types (18).
In this study, gelatin zymography was used to
measure concentrations of MMP-2 (72-kDa), MMP-9
(92-kDa), 130- and 225-kDa moieties. We examined
the relationship between the concentration and pro-
gression of colorectal and gastric cancers as evi-
denced by either histological grade or clinical stage,
and compared this to conventional tumor markers
including carcinoembryonic antigen (CEA) and cancer
antigen 19-9 (CA 19-9).
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Materials and methods
Patients
This prospective study was approved by the Ethics Commit-
tee of Wroclaw University of Medicine, Wroclaw, Poland.
The study included 47 patients with colorectal cancer, 34
patients with untreated gastric cancer, and 19 healthy vol-
unteers as normal controls. Colorectal and gastric cancer
was classified according to the histological grade (G) and
clinical stage (S). Histological grading was assessed accord-
ing to Sternberg (19). Clinical staging was assessed accord-
ing to Union Internacional Contra la Cancrum (NICC) tumor
node metastasis (TNM) classification, where post-surgical
histopathological classification (pTNM) was used (20).
Gelatin zymographic analysis
The gelatinolytic activity present in serum was determined
using gelatin zymographic analysis as described by Kleiner
and Stetler-Stevenson (21) with minor modifications. Serum
samples were diluted (1:75) in formulated buffer (5 mM Tris-
HCl; Sigma, St. Louis, MO, USA), 0.1 mM CaCl2 (Sigma), and
1 mM 1,10-phenathroline (Sigma), pH 7.5) mixed with 4x
sample buffer. Samples were electrophoresed in duplicate
(20 mL/lane) on 7.5% SDS-PAGE (0.75 mm thickness) con-
taining gelatin (Sigma) (2 mg/mL) using mini-PROTEAN II
system (Bio-Rad, Hercules, CA, USA). The concentrated
supernatant of the cell culture media (HT-1080 cell line) was
used as positive controls for MMP-2 and -9. Following elec-
trophoresis, gels were washed 3 times (20 min each) in 2.5%
Triton-X 100 (Sigma-Aldrich, Steinheim, Germany), and then
incubated in Tris buffer w0.05 M Tris-HCl, containing 0.01 M
CaCl2, 0.2 M NaCl (Merck, Darmstadt, Germany)x and 0.05%
NaN3 (Sigma), pH 7.5 at 378C for 18 h. Gels were stained with
0.5% Coomassie brilliant blue R250 (Sigma) in 30% methanol
(POCh, Poland), and 10% acetic acid (POCh) (100 mL/gel) for
3 h with shaking at room temperature, and then destained
with three changes of 30% methanol, and 10% acetic acid
(100 mL/gel) for 15, 30, and 60 min of destain time, respec-
tively. Gels were scanned and analyzed with SigmaGel soft-
ware (Jandel Corporation, San Rafael, CA, USA), where the
integrated area of each gelatinolytic band was measured.
The size of the gelatinolytic bands were expressed in arbi-
trary units (AU).
Determination of tumor markers in human sera
CEA and CA 19-9 were measured in human sera, using CEA-
IRMA (immunoradiometric assay) (Radioisotope center,
Polatom, Warsaw, Poland) and CA 19-9 IRMA (CIS Bio Inter-
national, Gif-sur-Yvette Cedex, France) kits, respectively.
Statistics
Data are expressed as mean"SEM. Non-parametric analysis
wKruskal-Wallis analysis of variance (ANOVA)x was used to
compare differences between groups. Post hoc analysis by
Dunn’s test was performed when the p-0.05. Correlations
between the two groups were analyzed using Pearson
moment or Spearman R test for parametric and non-para-
metric variables, respectively. Statistical analysis was per-
formed using statistical software (GraphPad Software, Inc.,
San Diego, CA, USA). A value of p-0.05 was considered
statistically significant.
Results
Patient demographics
Patients with colorectal (ns47, 64"2 years) and gas-
tric (ns34, 64"2 years) cancer were grouped accord-
ing to their histological grade and clinical stage.
Histological grading showed that the number of
patients with colorectal cancer GI, GII and GIII were
5, 38 and 4, respectively. Histological grades of
patients with gastric cancer GI, GII and GIII were 2, 16
and 16, respectively. Clinical staging revealed that the
number of patients with colorectal cancer S0, SI, SII,
SIII and SIV were 0, 4, 16, 11 and 16, respectively.
Staging of patients with gastric cancer SIa, SIb, SII,
SIIIa, SIIIb and SIV were 0, 0, 6, 0, 10 and 18, respec-
tively (Table 1).
Gelatin zymographic analysis
Zymographic analysis of serum revealed four gelati-
nolytic bands corresponding to MMP-2 (72-kDa),
MMP-9 (92-kDa), 130- and, 225-kDa gelatinolytic
bands. In normal controls and patients with colorectal
and gastric cancer, there were no significant differ-
ences in the gelatinolytic activities between females
and males.
Serum levels of MMP-2
Levels of serum MMP-2 in patients with colorectal
(426.5"35.8 AU) and gastric (386.1"26.3 AU) cancer
were not significantly higher than in normal
controls (319.7"28.3 AU) (Figure 1A). No significant
differences were found between histological grade or
clinical stage in patients with colorectal or gastric
cancer.
Serum levels of MMP-9
Serum levels of MMP-9 in patients with colorectal
(1324"85 AU) or gastric cancer (1234"77 AU) were
significantly higher than values seen in normal con-
trols (960"79 AU) (Figure 1B). For patients with colo-
rectal cancer, differences in MMP-9 levels between
histological grade or clinical stage and normal con-
trols were not significant (Figure 2A and B). However,
in patients with gastric cancer, significant differences
were found in MMP-9 levels in GI and SIII cancer
when compared to normal controls (Figure 2C and D).
Serum levels of 130-kDa and 225-kDa gelatinolytic
bands
Serum levels of 130-kDa gelatinolytic band in patients
with colorectal (259"29 AU) or gastric (250"27 AU)
cancer were significantly higher than in normal con-
trols (116"24 AU) (Figure 1C). Significant differences
were found in the levels of 130-kDa gelatinolytic band
of GI, GII, SIIIb, and SIV in gastric cancer patients (Fig-
ure 2C and D) compared to normal controls. In addi-
tion, for patients with colorectal cancer, significant
differences were found in the level of 130-kDa gelati-
nolytic band of GII and SII cancer compared to normal
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Table 1 Demographic data of normal controls and patients with colorectal and gastric cancer.
Control Colorectal cancer Gastric cancer
ns19 ns47 ns34
Mean age, years 54"2 64"2 64"2
Female/male 8/11 20/27 10/24
Histological grade
Grade I
Mean age, years – 68"4 54"1
Female/male 3/2 1/1
Grade II
Mean age, years – 65"2 64"3
Female/male 14/24 5/11
Grade III
Mean age, years – 53"5 66"3
Female/male 3/1 4/12
Clinical stage
Stage 0
Mean age, years –  –
Female/male
Stage Ia
Mean age, years – – 
Female/male
Stage Ib
Mean age, years – – 
Female/male
Stage I
Mean age, years – 63"6 –
Female/male 2/2
Stage II
Mean age, years – 64"3 65"4
Female/male 6/10 2/4
Stage IIIa
Mean age, years – – 
Female/male
Stage IIIb
Mean age, years – – 64"4
Female/male 2/8
Stage III
Mean age, years – 65"4 –
Female/male 6/5
Stage IV
Mean age, years – 65"2 63"4
Female/male 6/10 6/12
–, not applicable; , no patients in this category.
controls. A modest increase was seen in patients with
GIII, SIII, and SIV cancer (Figure 2A and B).
Serum levels of 225-kDa gelatinolytic band in
patients with colorectal cancer (284"24 AU) or gastric
cancer (285"20 AU) were significantly higher than
those in normal controls (172"18 AU) (Figure 1D).
There were significant differences in the levels of 225-
kDa gelatinolytic band in GII, GIII, SIIIb, and SIV of
gastric cancer (Figure 2C and D) and in GII of colorec-
tal cancer compared to that of normal controls (Figure
2A). In patients with colorectal cancer, there were no
significant differences in 225-kDa gelatinolytic band
levels with respect to clinical stages and normal con-
trols (Figure 2B).
Serum concentrations of CEA and CA 19-9
There were no significant differences in CEA and CA
19-9 between females and males comprising the
control group or patients with colorectal, or gastric
cancer. In patients with colorectal cancer, serum con-
centrations of CEA (19.3"5.9 ng/mL) were signifi-
cantly higher than in normal controls (0.7"0.2 ng/mL)
(p-0.001). The serum CEA concentrations with
respect to histological grade and clinical stage were
significantly different from that of normal controls
(p-0.01 for both) (Figure 3A and B).
For patients with gastric cancer, serum concentra-
tions of CEA (13.9"4.8 ng/mL) were significantly
higher compared with normal controls (p-0.05). The
serum concentration of CEA in patients with SIV can-
cer was higher than values seen in normal controls
(Figure 3B). There was no significant difference with
respect to histological grade and normal control
(Figure 3A).
For patients with colorectal cancer (29.4"11.9
U/mL), serum concentrations of CA 19-9 were modestly
higher than values seen in normal controls (7.8"1.3
U/mL), but the difference was not significant. Signifi-
cant difference was found in the concentrations of CA
19-9 in patients with SIV cancer compared to normal
controls (Figure 3D). Serum CA 19-9 concentrations
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Figure 1 Representative zymograms and levels of MMP-2 (A), MMP-9 (B), 130-kDa (C) and 225-kDa (D) gelatinolytic bands
in normal controls, and patients with colorectal and gastric cancer.
**p-0.001 and *p-0.05 vs. control (ANOVA).
Figure 2 Levels of MMP-9, 130-kDa, and 225-kDa gelatinolytic bands in the sera of patients with colorectal (ns47; A and B)
and gastric (ns34; C and D) cancer in relation to histological grades (GI–GIII) (left panel) and clinical stage (SI–SIV) (right
panel).
**p-0.001 and *p-0.05 vs. control (ANOVA).
with respect to histological grade and normal controls
were not significantly different (Figure 3C).
In patients with gastric cancer, serum concentra-
tions of CA 19-9 (71.4"20.7 U/mL) were significantly
higher than values seen in normal controls
(7.8"1.3 U/mL) (p-0.01). Significant differences were
found in the concentrations of CA 19-9 in patients
with GII and SIV cancer compared to those of normal
controls (Figure 3C and D).
Correlations between measured serum parameters
Significant and positive correlation was found
between MMP-9 and 130-kDa MMP-9 and 225-kDa
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Figure 3 Serum levels of CEA (A and B) and CA 19-9 (C and D) in colorectal and gastric cancer in relation to histological
grade (GI–GIII) (left panel) and clinical stage (SI–SIV) (right panel).
**p-0.001 and *p-0.05 vs. control (ANOVA).
values in normal controls (rs0.85, p-0.0001; rs0.66,
ps0.002, respectively), patients with colorectal
(rs0.85, p-0.0001; rs0.89, p-0.0001) and gastric
(rs0.71, p-0.0001; rs0.61, p-0.0001) cancer (Figure
4). No significant correlation was seen between
MMP-2 and 130-kDa, MMP-2 and 225-kDa levels in
normal controls and patients with colorectal or gastric
cancer.
Discussion
MMP-2 and -9 are the most extensively studied MMPs
in various types of cancer. However, there is little
information about the actual role of 130- and 225-kDa
gelatinolytic bands. In this study, the significant
increase in serum levels of MMP-9 in patients with
colorectal or gastric cancer is consistent with other
studies using either gelatin zymography or ELISA to
measure MMP-9 in serum (10), plasma (3) and paired
samples of colorectal cancer and normal colon muco-
sa (3, 13). However, there was no correlation between
MMP-9 levels and histological grade or clinical stage
of the tumor. Despite large variations in samples, Bak-
er and Leaper (11) found that levels of MMP-9 corre-
lated with the Dukes staging and lymphatic invasion
of colorectal cancer (ns77). In addition, immunohis-
tochemical studies showed that either serum or tissue
MMP-9 expression was significantly correlated with
the stage of gastric cancer (ns256) (8, 22, 23). How-
ever, others reported no significant correlation
between the grade or stage of cancer (ns53–192) and
the level of MMP-9 (2, 9, 10, 13) which is similar to
our observations. Although the relation between
serum MMP-9 levels and histological grade or clinical
stage is controversial, we believe that it is partly relat-
ed to differences in methods used by different stud-
ies. The significant increase in serum levels of MMP-9
in patients with colorectal and gastric cancers implies
that MMP-9 may be associated with tumor
progression.
It has been shown that the 130-kDa gelatinolytic
band is a complex of MMP-9 and neutrophil-derived
lipocalin-2 (NGAL), and the 225-kDa gelatinolytic band
corresponds to pro-MMP-9 dimers (24, 25). The sig-
nificant and positive correlations found between
MMP-9 levels and 130-kDa or 225-kDa gelatinolytic
bands in normal controls, patients with colorectal and
gastric cancer support 130-kDa and 225-kDa as con-
stituting the heterodimer and homodimer of MMP-9,
respectively (25). Also, the significant increase in the
130- and 225-kDa gelatinolytic bands in colorectal or
gastric cancer is in accordance with other reports (12,
16). This may reflect their biological abundance and
importance in the transformation of a tumor from the
benign to the malignant state, and may also indicate
their role in tumor progression. It is known that MMP-
9, when complexed to Lipocalin-2, is protected from
full inhibition by TIMP-1 and retains the capacity to
function as an auto-activator for non-complexedMMP-9
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Figure 4 Correlation between MMP-9 levels and 130 kDa or 225 kDa gelatinolytic band values in the sera of normal controls
(A and B, ns19), and patients with colorectal (C and D, ns47) or gastric (E and F, ns34) cancer.
(24). Experimental data suggest that increased
lipocalin-2 expression results in either significant
stimulation of tumor growth (26) or lipocalin-2 may
be a suppressor of colon cancer metastasis (27). How-
ever, we did not find any significant relationship
between serum 130-kDa and histological grade and
clinical stage in patients with colorectal or gastric
cancer.
Our results showed that serum levels of MMP-2 in
patients with colorectal or gastric cancer were mod-
estly higher than normal controls, which is consistent
with other observations using the same technique for
measurement in serum (28). Compared to other
reports where ELISA was used to determine MMP-2
in serum or plasma, there are conflicting results (3–5,
9, 10, 14, 29). We therefore suggest that zymographic
determination of MMP-2 is of limited value for tumor
grading, staging, and prognosis in either colorectal or
gastric cancer (5, 10).
In the present study, significant increases in serum
concentrations of CEA and CA 19-9 in patients with
colorectal and gastric cancers could provide powerful
and useful information regarding the progression of
these specific types of cancer, consistent with other
reports (30–33). Although the serum levels of MMP-
9, 130- and 225-kDa gelatinolytic bands showed sta-
tistical significance similar to that exhibited by
conventional tumor markers such as CEA and CA 19-
9, none of them significantly correlate with CEA or CA
19-9 expression in serum. This may indicate that
these are regulated independently from these tumor
markers (9). Interestingly, the increased serum levels
of gelatinolytic proteases could be related to neutro-
phil activation by some forms of gastrointestinal can-
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cers. Furthermore, MMP-9 is reportedly expressed in
normal cells, inflammatory conditions as well as in
tumors from diverse sites, including skin, lung,
breast, colo-rectum, liver, prostate, brain, bone mar-
row, and bone (34).
Gelatin zymography offers several features that
render this technique particularly useful: several pro-
teases (latent and active forms) of different molecular
weights can be detected and evaluated with a single
gel, a small amount of serum (0.2 mL) is used, and
picogram quantities can be quantified. In addition,
positive controls for both MMP-2 and -9 can be
analyzed on each gel to alleviate inter- and intra-gel
variation. However, the zymographic technique is dif-
ficult to scale up for routine use. Nonetheless, these
features compare favorably with other methods,
including ELISAs and Western blots, without the need
for specialized and expensive materials such as anti-
bodies (21, 35). On the other hand, discrepancies in
results obtained by ELISA in colorectal or gastric can-
cer may be due to differences in monoclonal antibod-
ies that recognize various forms of MMPs or their
complexes with natural inhibitors TIMPs or a-macro-
globulin. Gelatin zymography measures the total
amount of MMPs by its proteolytic activity on gelatin
substrate, because SDS dissociates enzyme-inhibitor
complexes (36).
In conclusion, serum concentrations of MMP-2were
not significantly increased in patients with colorectal
and gastric cancer. This may limit its value in these
types of cancer. On the other hand, MMP-9, 130-kDa
and 225-kDa gelatinolytic bands did significantly
increase in patients with either colorectal or gastric
cancer, and this increase is related to increases in pro-
teolytic degradation of the extracellular matrix and
matrix invasion (37). However, none of these signifi-
cantly correlate with histological grade or clinical
stage; thus we do not believe that their increase in
serum is related to the extent of invasion and tumor
progression. This may warrant measurement of these
parameters in parallel with other conventional mark-
ers in a study of patients with these gastrointestinal
cancers. Further studies are required to evaluate the
benefits of determination of these parameters as
prognostic or predictive biomarkers for screening,
diagnosis and follow-up patients with colorectal or
gastric cancer. This may improve diagnostic and
therapeutic strategies.
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